HOW TO INCORPORATE MRD IN CLINICAL TRIALS

HOW TO INCORPORATE MRD IN CLINICAL TRIALS

Bibliographic Details
Main Author:	Jesus San-Miguel
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000829512.46921.c8

Similar Items

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01)

P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM)
by: Bruno Paiva, et al.
Published: (2023-08-01)

MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
by: Giovanni Riva, et al.
Published: (2021-09-01)

MRD negativity: considerations for older adults with multiple myeloma
by: Hira Mian, et al.
Published: (2023-11-01)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
by: F. B. Askeland, et al.
Published: (2022-06-01)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
by: Madlen Jentzsch, et al.
Published: (2023-08-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
by: Nigel Russell, et al.
Published: (2023-08-01)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
by: David G. Coffey, et al.
Published: (2023-09-01)

PCR-based MRD testing for acute lymphoblastic leukaemia in India
by: Rubina Islam, et al.
Published: (2017-01-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

MRD-based word sense disambiguation : further extending lesk
by: Baldwin, Timothy, et al.
Published: (2010)

Toxicity effect of nanoparticles in various mrd systems towards seabass /
by: Syamir Nadia Mohd.Yacob, 1988-, et al.
Published: (2015)

Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL.
by: Moppett, J, et al.
Published: (2002)

Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD
by: Crystal L Mackall, et al.
Published: (2023-02-01)

Recent Structural Developments and Applications of Magnetorheological Dampers (MRD): A Review
by: Yanjuan Zhang, et al.
Published: (2023-03-01)

Utility of flow cytometry screening before MRD testing in multiple myeloma
by: Vandana Panakkal, et al.
Published: (2023-04-01)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
by: Angelo Maiolino, et al.
Published: (2023-05-01)

Design and Experiment on Single-Chip Microprocessor for MRD Coupling Sensing and Control
by: Ying-Qing Guo, et al.
Published: (2012-09-01)

P1402: INFUSION OF 14 DAYS BLINATUNOMAB IN COMBINATION WITH CHEMOTHERAPY FOR 46-DAY MRD+ PEDIATRIC B-ALL PATIENTS IN INTERMEDIATE/HIGH-RISK GROUP RESULTS IN MRD CONVERSION.
by: Changwen Xue, et al.
Published: (2023-08-01)

Molecular MRD status and outcome after transplantation in NPM1-mutated AML
by: Dillon, R, et al.
Published: (2020)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
by: Katharina Kriegsmann, et al.
Published: (2020-08-01)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
by: Kazuhito Suzuki, et al.
Published: (2021-09-01)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
by: Elisa Meddi, et al.
Published: (2023-02-01)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
by: Radhika Bansal, et al.
Published: (2023-04-01)

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia
by: O'Connor, D, et al.
Published: (2017)

Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection
by: Thien-Phuc Nguyen Hoang, et al.
Published: (2024-02-01)

How to incorporate /
by: 171063 Diamond, Michael B.
Published: (1996)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
by: Rania Gaspo, et al.
Published: (2023-08-01)

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1999)

Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)
by: Roger G. Owen
Published: (2019-06-01)

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
by: Anne Tierens, et al.
Published: (2021-03-01)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
by: Alexandra Teixeira, et al.
Published: (2023-02-01)

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol
by: Guilherme Navarro Nilo Giusti, et al.
Published: (2023-08-01)

Evaluation of MRD-status in post-induction period in pediatric patients with acute lymphoblastic leukemia.
by: Meri Shervashidze, et al.
Published: (2022-10-01)

Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside
by: Xinyue Deng, et al.
Published: (2022-09-01)

Improved MRD 4H-SiC MESFET with High Power Added Efficiency
by: Shunwei Zhu, et al.
Published: (2019-07-01)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
by: Luciano Costa, et al.
Published: (2023-08-01)

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
by: Mark J Levis, et al.
Published: (2023-08-01)